Merck Charges Jubilant With Infringement Of Januvia Patent
Merck & Co has sought to block Jubilant Life Sciences over the alleged infringement of its patent on Januvia (sitagliptin) in India, continuing with a string of IPR-related legal action in the country.
You may also be interested in...
Merck & Co has moved to fend off a clutch of smaller Indian players that allegedly contract manufacture and export two of its diabetes therapies, or hope to introduce copies of these on the domestic market, infringing on its patents.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.